- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Johan Vansteenkiste on Atezolizumab in NSCLC
Johan F. Vansteenkiste, MD, PhD, professor of Internal Medicine at Katholieke Universiteit Leuven, Belgium, discusses the primary analysis of the phase II POPLAR study, which looked at atezolizumab versus docetaxel in patients with non–small cell lung cancer (NSCLC).
Johan F. Vansteenkiste, MD, PhD, professor of Internal Medicine at Katholieke Universiteit Leuven, Belgium, discusses the primary analysis of the phase II POPLAR study, which looked at atezolizumab versus docetaxel in patients with non—small cell lung cancer (NSCLC).
In the primary analysis, atezolizumab showed an improved survival advantage over docetaxel compared with results shown in the interim analysis, says Vansteenkiste. This may be due to the fact that immunotherapy tends to have a delayed onset. With longer follow-up, more separation of the survival curves is seen.
Because of this delayed response, results may even further improve, says Vansteenkiste.
<<<